荣昌生物制药（烟台）股份有限公司（股票代码：09995）于2026年8月3日发布公告，披露该公司在当日通过上海证券交易所集中竞价交易方式回购A股股份28,040股，占本次回购前已发行股本（不含库藏股）约0.0079%。回购价格区间为每股人民币108.30元至人民币109.23元，合计支付约人民币304.85万元。回购完成后，公司已发行股本维持于355,896,244股不变，其中不含库藏股的已发行股份减少至355,661,060股，库藏股数量增至235,184股。
据公告，前次股本数据中，公司截至2026年7月31日的已发行股份（不含库藏股）为355,689,100股，库藏股207,144股。本次回购的股份拟用于员工股权激励计划；如在回购实施完成公告后3年内未能使用完毕，未使用部分将予以注销。公司表示，本次回购行为遵守了相关上市规则及适用法律。公告由董事王威东签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.